These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 38931409)

  • 21. 6-Methyluracil derivatives as acetylcholinesterase inhibitors for treatment of Alzheimer's disease.
    Zueva IV; Semenov VE; Mukhamedyarov MA; Lushchekina SV; Kharlamova AD; Petukhova EO; Mikhailov AS; Podyachev SN; Saifina LF; Petrov KA; Minnekhanova OA; Zobov VV; Nikolsky EE; Masson P; Reznik VS
    Int J Risk Saf Med; 2015; 27 Suppl 1():S69-71. PubMed ID: 26639718
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel strategies for the fight of Alzheimer's disease targeting amyloid-β protein.
    Xie Y; Wang Y; Jiang S; Xiang X; Wang J; Ning L
    J Drug Target; 2022 Mar; 30(3):259-268. PubMed ID: 34435898
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of amyloid beta-directed antibodies against Alzheimer's disease: Twists and turns.
    Lu D; Dou F; Gao J
    Drug Discov Ther; 2023; 17(6):440-444. PubMed ID: 38220210
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Navigating the Alzheimer's Treatment Landscape: Unraveling Amyloid-beta Complexities and Pioneering Precision Medicine Approaches.
    Patwekar M; Patwekar F; Khan S; Sharma R; Kumar D
    Curr Top Med Chem; 2024; 24(19):1665-1682. PubMed ID: 38644708
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monoclonal antibody therapy for Alzheimer's disease focusing on intracerebral targets.
    Gu X; Qi L; Qi Q; Zhou J; Chen S; Wang L
    Biosci Trends; 2024 Mar; 18(1):49-65. PubMed ID: 38382942
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ACH2.0/E, the Consolidated Theory of Conventional and Unconventional Alzheimer's Disease: Origins, Progression, and Therapeutic Strategies.
    Volloch V; Rits-Volloch S
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892224
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exploring Dimethylsulfoniopropionate as a potential treatment for Alzheimer's disease: A study using the 3 × Tg-AD mouse model.
    Sun F; Huang X; Wang H; Lin B; Li H; Wang X; Liu Q
    Phytomedicine; 2024 Jul; 130():155788. PubMed ID: 38838634
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Review on Tau Targeting Biomimetics Nano Formulations: Novel Approach for Targeting Alzheimer's Diseases.
    Singh A; Maheshwari S; Yadav JP; Varshney AP; Singh S; Prajapati BG
    Cent Nerv Syst Agents Med Chem; 2024; 24(3):294-303. PubMed ID: 38646682
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.
    Dinda B; Dinda M; Kulsi G; Chakraborty A; Dinda S
    Eur J Med Chem; 2019 May; 169():185-199. PubMed ID: 30877973
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alzheimer's Disease Immunotherapy: Current Strategies and Future Prospects.
    Aljassabi A; Zieneldien T; Kim J; Regmi D; Cao C
    J Alzheimers Dis; 2024; 98(3):755-772. PubMed ID: 38489183
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is Beta-Amyloid Accumulation a Cause or Consequence of Alzheimer's Disease?
    Wang S; Mims PN; Roman RJ; Fan F
    J Alzheimers Parkinsonism Dement; 2016; 1(2):. PubMed ID: 28815226
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent Progress Towards Vaccines and Antibody-based Therapies Against Alzheimer's Disease.
    Ji W; Gong B; Jin H; Chen X; Li P; Cheng W; Zhao Y; He B; Zhuang J; Gao J; Yin Y
    Mini Rev Med Chem; 2021; 21(19):3062-3072. PubMed ID: 34353254
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Passive Immunotherapies Targeting Amyloid-
    Marković M; Milošević J; Wang W; Cao Y
    Mol Pharmacol; 2023 Dec; 105(1):1-13. PubMed ID: 37907353
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Basic Biology of BACE1: A Key Therapeutic Target for Alzheimer's Disease.
    Cole SL; Vassar R
    Curr Genomics; 2007 Dec; 8(8):509-30. PubMed ID: 19415126
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advances in aptamers against Aβ and applications in Aβ detection and regulation for Alzheimer's disease.
    Zheng Y; Zhang L; Zhao J; Li L; Wang M; Gao P; Wang Q; Zhang X; Wang W
    Theranostics; 2022; 12(5):2095-2114. PubMed ID: 35265201
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulation of beta-amyloid for the treatment of Alzheimer's disease: Research progress of therapeutic strategies and bioactive compounds.
    Qiu W; Liu H; Liu Y; Lu X; Wang L; Hu Y; Feng F; Li Q; Sun H
    Med Res Rev; 2023 Jul; 43(4):1091-1140. PubMed ID: 36945751
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Alzheimer's disease drug development landscape.
    van Bokhoven P; de Wilde A; Vermunt L; Leferink PS; Heetveld S; Cummings J; Scheltens P; Vijverberg EGB
    Alzheimers Res Ther; 2021 Nov; 13(1):186. PubMed ID: 34763720
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative.
    Veitch DP; Weiner MW; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Morris JC; Petersen RC; Saykin AJ; Shaw LM; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2019 Jan; 15(1):106-152. PubMed ID: 30321505
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aβ regulation-based multitarget strategy for drug discovery against Alzheimer's disease.
    Guo X; Jiang W; Li C; Zhu Z; Shen X
    Rev Neurosci; 2015; 26(1):13-30. PubMed ID: 25720054
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.